Drug General Information (ID: DDIV54CMJZ)
Drug Name			Yellow Fever Vaccine		Drug Info		Brexucabtagene autoleucel		Drug Info
Drug Type		Vaccine				Autologous cell transplant
Therapeutic Class		Vaccine				Antineoplastics

Mechanism of Yellow Fever Vaccine-Brexucabtagene autoleucel Interaction (Severity Level: Major)
Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph
Drug Name		Yellow Fever Vaccine				Brexucabtagene autoleucel
Mechanism		Vaccine or toxoid				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Vaccine/toxoid
		Factor Description		The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response.
Mechanism Description		Antagonize the effect of Yellow Fever Vaccine when combined with Brexucabtagene autoleucel

Recommended Action
Management		In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.

References
1	Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998).
2	Product Information. Attenuvax (measles virus vaccine, live, attenuated). Merck &amp Co, Inc, West Point, PA.
3	Product Information. YF-Vax (yellow fever vaccine). sanofi pasteur, Swiftwater, PA.